Share This
Create Your Own Business Intelligence Website
Input the stock code or the company name     Search  

<01177.HK> - Sino Biopharmaceutical Limited

 Basic Datum
Company name Lot P/E P/B EPS DPS
SINO BIOPHARM 1000 55.79 12.0134 0.2581 0.06
Profile Information Data Financial Ratios Profit Loss Cash Flow Balance Earnings Dividend
 Company Rating
Date Broker Company name Rating Target
 Company performance - Published
Date Company name Turnover* Profit* % Dividend
2020-07-17 野村發表報告稱中國生物制藥6月份內地醫院市場已回復至公共衛生事件前的八成水平,但就投資者的擔心,該公司如今未提供2020年業績指引,公司預測腫瘤科菌物2020年銷售額可達80億元人幣(下同),當中有50%是來自安羅替尼。此外,中國生物制藥預測布地奈德混懸液2020年可帶來7億元的營收,野村相信當下醫院市場逐步復蘇,今年上半年公司收入將同比提升5%。
2020-07-31 中國生物制藥有限公司宣布,其治療急性髓系白血病(「AML」)藥物注射用鹽酸伊達比星(商標名:安必健)(包括5MG及10MG兩個規格)已取得NMPA頒發藥品注冊證書,且視同透過仿制藥質量和療效一致性評價。伊達比星是國內外指南一致推薦的AML基石治療藥物。中國生物制藥開發的安必健是全國同品種首個透過一致性評價的產品。
2020-07-31 內地醫藥股午後繼續走強,阿里健康漲10.05%,中國生物制藥漲8.75%,藥明生物漲6.97%,復星醫藥漲5.44%,平安好醫生漲5.34%,信達生物漲5.28%。
2020-08-07 智通財經APP獲悉,野村現在將中國生物制藥目標價調降,由16.9港元降至11.6港元,保持「買進」評級。
 Top Gain / Loss Show All Charts 
Name Updated Value Change Change %
HSI 08-07 16:08 24531.6  398.96  1.6%
SINO BIOPHARM 08-07 16:08 9.7  0.21  2.21%

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2020Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.